SUBSCRIBE
SUBSCRIBE

Phase I

Investors Sigh With Relief as Biogen's Alzheimer's Drug Delivers in Early-Stage Study
Drug Development
3 Reasons That Make Biogen the King of a Crumbling Empire
November 11, 2016
 · 
2 min read
Biotech Vets Launch Arrakis With $38 Million and Will be Helmed By Biogen Alum Michael Gilman
Drug Development
Sanofi and Novartis AG are the Worst Culprits in Reporting Clinical Trial Data, Shire the Best
November 4, 2016
 · 
2 min read
Gilead Suffers Another R&D Setback as Myelofibrosis Drug Flops in Phase III, Gives Credence to Acquisition Urgency
Drug Development
Gilead Drops Another Bombshell, Will Shift R&D Cash Away From Hep C
November 3, 2016
 · 
2 min read
Drug Development
10 Drugs That Could be Johnson & Johnson’s New Blockbusters
November 2, 2016
 · 
1 min read
Wall Street's Top Biotech Analyst Loves These 2 Life Science Stocks
Drug Development
The $40 Billion NASH Market and the 3 Biotechs That Stand to Profit From it
November 1, 2016
 · 
3 min read
What You Missed: Nippon Fine Chemical Formed Human Barricade to Stop FDA Employee
Drug Development
FDA Slaps Partial Hold on Bay Area Firm Aduro Biotech’s Cancer Vaccine Trial
October 24, 2016
 · 
2 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Drug Development
2 Biotechs Face Key Decisions in Mid-Fourth Quarter
October 21, 2016
 · 
2 min read
Why Booming Vertex is on Its Way to Becoming Gilead's Mini-Me
Drug Development
After Hep C Flop, Has Vertex Learned From Its Past Mistakes?
October 18, 2016
 · 
3 min read
For Sale: Pfizer's $3.4 Billion Consumer Healthcare Business
Drug Development
How Pfizer is Quietly Rebuilding Its Alzheimer’s Pipeline
October 18, 2016
 · 
2 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Drug Development
A Look at CRISPR, ‘Biotech’s Biggest Discovery of the Century,’ and the 3 Companies Knee Deep in It
October 17, 2016
 · 
3 min read
Load More
PRESS RELEASES
Drug Development
Skye Bioscience Begins Dosing Fifth of Six Cohorts in Phase 1 Clinical Trial of Novel CB1R Agonist
May 17, 2023
 · 
3 min read
Drug Development
DEBIOPHARM LAUNCHES PHASE 1/2 COMBINATION TRIAL INVESTIGATING BRAIN-PENETRANT SELECTIVE WEE1 INHIBITOR FOR BRAIN CANCER PATIENTS
May 17, 2023
 · 
5 min read
Drug Development
Micron Biomedical Announces Positive Measles and Rubella Vaccination Results from First Clinical Trial of Microarray Injection-Free Vaccine Delivery in Children
May 17, 2023
 · 
4 min read
Drug Development
ImmunoBrain Checkpoint Doses First Patients in Phase 1b Clinical Trial of IBC-Ab002 for Alzheimer’s Disease
May 17, 2023
 · 
4 min read
Drug Development
Ultragenyx Receives FDA Agreement to Expand Ongoing Global Phase 1/2 Trial Evaluating GTX-102 in Patients with Angelman Syndrome in the U.S.
May 17, 2023
 · 
7 min read
Drug Development
Indapta Therapeutics Announces U.S. FDA Clearance of IND for IDP-023, an Allogeneic Natural Killer (NK) Cell Therapy for Cancer
May 17, 2023
 · 
2 min read
Drug Development
Novadip Biosciences SA Announces First Pediatric Patient with Congenital Pseudoarthrosis of the Tibia Undergoes Implantation with NVD-003, an Autologous Tissue Regeneration Product, in Phase 1b/2a US/EU Clinical Trial
May 17, 2023
 · 
4 min read
Drug Development
TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting
May 17, 2023
 · 
9 min read
Drug Development
Transcenta Announces Encouraging Phase I Clinical Data of TST002 (Blosozumab) in Chinese Patients with Reduced Bone Mineral Density
May 16, 2023
 · 
5 min read
Drug Development
Myrtelle Announces Presentation of Positive 6-month Post-Treatment Data in Its First-in-Human Clinical Study of rAAV-Olig001-ASPA Gene Therapy in Canavan Disease at the American Society of Gene and Cell Therapy 26th Annual Meeting
May 16, 2023
 · 
5 min read
Business
Olatec Therapeutics Announces the Completion of First Dose Cohort in an Innovative Trial Investigating Olatec’s NLRP3 Inhibitor Dapansutrile and Merck’s Keytruda®
May 16, 2023
 · 
11 min read
Drug Development
Triumvira Immunologics to Present Clinical Data from Phase I/II Trial TACTIC-2 Investigating TAC01-HER2 at the 2023 ASCO Annual Meeting
May 16, 2023
 · 
2 min read
Drug Development
Regulus Therapeutics Advances to Cohort 2 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
May 16, 2023
 · 
6 min read
Drug Development
Kimera® Labs Receives FDA Phase I/IIa IND Approval For Its MSC Exosomes Human Study
May 16, 2023
 · 
1 min read
Drug Development
Iterion Therapeutics Announces the Initiation of a Phase 1 Clinical Trial for Tegavivint in Patients with c-Myc-overexpressing Relapsed or Refractory Large B-Cell Lymphomas
May 16, 2023
 · 
4 min read
Business
Immunai and Baylor College of Medicine Provide Updated Interim Phase 1 Results for anti-GD2 CAR NKT-Cell Therapy in Relapsed/Refractory Neuroblastoma
May 15, 2023
 · 
4 min read
Drug Development
Skye Bioscience Receives Positive Safety Review in First Multiple-Administration Cohort of Phase 1 Study of SBI-100 Ophthalmic Emulsion
May 15, 2023
 · 
3 min read
Drug Development
Invirsa Completes Enrollment of Phase 1/2a Dry Eye Study
May 15, 2023
 · 
3 min read
Business
Therapeutic Solutions International Spin-Off Res Nova Bio Partners with Cure Stat Rx to Manufacture First in Class Breast Cancer Immunotherapy Product FloraStilbene™
May 15, 2023
 · 
2 min read
Drug Development
Therini Bio Initiates First-In-Human Dosing in Phase 1 Trial of THN391, a Fibrin-Targeting Therapeutic Candidate for Alzheimer’s Disease
May 15, 2023
 · 
4 min read
Load More